微小RNA-597在肝癌组织中的表达水平变化及其临床意义

Expression of microRNA-597 in hepatocellular carcinoma and its clinical significance

目的探讨微小RNA(miR)-597在肝癌组织中的表达及其与临床病理和预后的关系。方法选取南阳市中心医院2016年5月至2018年5月收集的126例肝癌和癌旁组织作为研究对象,采用荧光定量PCR分析癌旁和肝癌组织中miR-597表达水平;分析miR-597表达水平与肝癌患者临床病理特征(年龄、性别、肿瘤直径、乙型肝炎、门静脉癌栓、组织分级、TNM分期、淋巴结转移)的关系,并比较miR-597表达阳性和阴性患者3年生存率和中位生存期。采用单因素卡方和多因素回归分析miR-597表达与临床病理特征和预后的关系。结果癌旁组织miR-597表达水平(1.28±0.28)明显高于肝癌组织miR-597表达水平(0.41±0.11),差异有统计学意义(t=3.991,P<0.05)。中高分化患者肝癌组织中miR-597表达水平(0.82±0.15)明显高于低分化患者肝癌组织(0.31±0.11),差异有统计学意义(t=3.047,P<0.05)。Ⅰ~Ⅱ期患者肝癌组织miR-597表达水平(0.70±0.12)明显高于Ⅲ~Ⅳ期患者肝癌组织(0.29±0.16),差异有统计学意义(t=3.280,P<0.05)。肝癌伴乙型肝炎患者肝癌组织miR-597表达水平(0.39±0.14)明显低于肝癌无乙型肝炎患者(0.76±0.13),差异有统计学意义(t=3.338,P<0.05)。门静脉癌栓患者组织miR-597水平(0.36±0.17)明显低于无门静脉癌栓患者肝癌组织(0.69±0.15),差异有统计学意义(t=3.874,P<0.05)。淋巴结转移患者肝癌组织miR-597表达水平(0.29±0.17)明显低于无淋巴结转移患者(0.84±0.15),差异有统计学意义(t=4.309,P<0.05)。miR-597高表达患者生存时间(29.5个月)明显高于miR-597低表达患者生存时间(16.4个月),差异有统计学意义(Log-rank=5.905,P<0.05)。miR-597高表达患者术后3年生存率(35/68,51.47%)高于miR-597低表达组患者术后3年生存率(12/58,20.69%),差异有统计学意义(Log-rank=5.046,P<0.05)。单因素方差分析显示,组织分级、TNM分期、门静脉癌栓、乙型肝炎阳性、淋巴结转移是影响肝癌组织miR-597表达的危险因素(P<0.05)。结论miR-597在肝癌组织中表达水平下调,与患者临床病理特征和预后明显相关。

Objective To investigate Expression of miR-597 in hepatocellular carcinoma and its clinical significance.Methods 126 cases of liver cancer and adjacent tissues in our hospital from May 2016 to May 2018 were selected as the research objects.The expression level of miR-597 in adjacent and adjacent liver cancer tissues was analyzed by fluorescence quantitative PCR;The relationship between miR-597 expression level and clinicopathological features(age,gender,tumor diameter,hepatitis B,portal vein tumor thrombus,tissue grade,TNM stage and lymph node metastasis)of patients with liver cancer was analyzed,and the 3-year survival rate and median survival time of patients with positive and negative miR-597 expression were compared.The relationship between miR-597 expression and clinicopathological features and prognosis was analyzed by univariate chi square and multivariate regression.Results The expression level of miR-597 in adjacent tissues(1.28±0.28)was significantly higher than that in liver cancer tissues(0.41±0.11),and the difference was statistically significant(t=3.991,P<0.05).The expression level of miR-597 in liver cancer tissues of moderately and highly differentiated patients(0.82±0.15)was significantly higher than that in liver cancer tissues of poorly differentiated patients(0.31±0.11),the(t=3.047,P<0.05).The expression level of miR-597 in stageⅠ-Ⅱpatients was significantly higher than that in stageⅢ-Ⅳpatients(0.29±0.16,t=3.280,P<0.05).The expression level of mir-597 in liver cancer with hepatitis B(0.39±0.14)was significantly lower than that in liver cancer without hepatitis B(0.76±0.13,t=3.338,P<0.05).The level of miR-597 in patients with portal vein tumor thrombus(0.36±0.17)was significantly lower than that in patients with liver cancer without portal vein tumor thrombus(0.69±0.15,t=3.874,P<0.05).The expression level of miR-597 in liver cancer tissues of patients with lymph node metastasis(0.29±0.17)was significantly lower than that of patients without lymph node metastasis(0.84±0.15,t=4.309,P<0.05).The survival time of patients with high expression of miR-597(29.5 months)was significantly higher than that of patients with low expression of miR-597(16.4 months),and the difference was statistically significant(log rank=5.905,P<0.05).The 3-year survival rate of patients with high expression of miR-597(35/68,51.47%)was significantly higher than that of patients with low expression of miR-597(12/58,20.69%)(log rank=5.046,P<0.05).One way ANOVA showed that tissue grade,TNM stage,portal vein tumor thrombus,hepatitis B positive and lymph node metastasis were the risk factors affecting the expression of miR-597 in hepatocellular carcinoma(P<0.05).Conclusion The low expression of miR-597 in hepatocellular carcinoma is closely related to the clinicopathological features,prognosis.